VIVUS — Proxy Contest (May 2013)
50 slides from VIVUS's proxy contest presentation, May 7, 2013
Slide 1: Vivus – Why Change Is Needed Now
FIRST MANHATTAN CO. Vivus – Why Change Is Needed Now May 7, 2013
Slide 2: Forward-Looking Statements
Forward - Looking Statements FIRST MANHATTAN CO. DOES NOT ASSUME RESPONSIBILITY FOR INVESTMENT DECISIONS. THIS PRESENTATION DOES NOT RECOMMEND THE PURCHAS E O R SALE OF ANY SECURITY. UNDER NO CIRCUMSTANCES IS THIS PRESENTATION TO BE USED OR CONSIDERED AS AN OFFER TO SELL OR A SOLICITATION OF AN OFFE
Slide 3: Additional Information
Additional Information FIRST MANHATTAN CO., FIRST HEALTH, L.P., FIRST HEALTH LIMITED, FIRST HEALTH ASSOCIATES, L.P., FIRST BIOMED MANAGEMENT ASSOCIATES, LLC, FIRST BIOMED, L.P. AND FIRST BIOMED PORTFOLIO, L.P. (COLLECTIVELY, “FIRST MANHATTAN”) INTEND TO FILE WITH THE SECURITIES AND EXCHANGE COMMISSI
Slide 4: About First Manhattan Co.
About First Manhattan Co. • First Manhattan Co. (FMC) is one of the largest shareholders of VIVUS, Inc. and currently owns 9,716,604 shares or 9.7% of the Company – an investment worth approximately $119 million 1 • We are long - term investors in high - quality assets, and our interests are fully a
Slide 5: FMC's Investment Thesis – The Upside Potential of Qsymia is Enormous
FMC’s Investment Thesis – The Upside Potential of Qsymia is Enormous • The potential obesity market is huge and growing – More than one third of adults in the United States are obese 1 – In the E.U., approximately 17% of adults are obese 2 – There are approximately 125 million obese adults in the US
Slide 6: Why is FMC Seeking A Board Overhaul at Vivus?
Why is FMC Seeking A Board Overhaul at Vivus? • FMC has taken an activist approach towards Vivus as a last resort – Over our 50 year history, Vivus is not our first disappointing investment – But in this case, there is a clear and achievable path to change that can unlock value for all shareholders
Slide 7: Vivus Shareholders Have A Clear Choice
Vivus Shareholders Have A Clear Choice FMC’s Nominees • Offer the experience, ability and independence from management needed to unlock the enormous potential value at Vivus vs. The Vivus Board • Offers “more of the same” – a Board composed of members with strong ties to the CEO who we believe lack
Slide 8: Board and Management Have Destroyed Significant Stockholder Value
The Vivus Board And Management Have Destroyed Significant Stockholder Value FIRST MANHATTAN CO. Stock has fallen roughly 60% since the Company’s announcement that the FDA approved Qsymia – Wiping out roughly $1.9 billion of shareholder value from July 18, 2012 through April 15, 2013 8
Slide 9: Vivus Board Has Destroyed Value
The Vivus Board Has Destroyed Value We believe the Vivus Board: 1. Is underqualified 2. Is overpaid 3. Has excessive management representation 4. Is not economically aligned with shareholders’ interests 5. Has mismanaged the Qsymia launch 6. Is a poor steward of shareholders’ capital 7. Lacks transp
Slide 10: Vivus Board is Underqualified to Guide a Commercial Stage Obesity Company
In our view, the Vivus Board is underqualified to guide a commercial stage obesity company • Vivus’ Board is led by a long - standing CEO and is composed of legacy Board members who we believe lack the independence, judgment and necessary skills to commercialize Qsymia That's why the Board has faile
Slide 11: Board is Underqualified: Experience Comparison
1. The Vivus Board is Underqualified Vivus Nominating and Governance Committee Charter: “The Board as a whole should collectively possess a broad range of skills, expertise, industry and other knowledge, and business and other experience useful to effective oversight of the Company’s business” • Ore
Slide 12: Orexigen Board: Case Study in Solid Preparation for Commercialization
1. The Vivus Board is Underqualified Orexigen Board: Case Study In Solid Preparation For Commercialization By Creating A Board With The Right Skill Set And Experience David Endicott – Joined Board in 2012 – Currently serves as Corporate Vice President and President, Allergan Medical , Asia Pacific a
Slide 13: Board is Overpaid: Compensation vs Orexigen
For a high - quality Board, LESS compensation is more. Vivus Board members receive approximately three times the cash compensation and nearly five times the equity compensation of Orexigen’s “all star” Board 1 . Orexigen proves that high quality talent can be recruited for a fraction of what the Viv
Slide 14: The Board is Enriching Itself at Shareholders' Expense
Vivus’ Compensation Committee Charter states: “The Committee will review compensation and benefits paid to non - employee Directors once a year and recommend any changes considered appropriate to the full Board for its approval .” (emphasis added) 2. The Vivus Board is Overpaid The Board is enrichin
Slide 15: Overpaid: Use of RSUs is an Outlier
2. The Vivus Board is Overpaid • Vivus' use of RSU's is an outlier - The Board's incentives are not aligned with shareholder interests – Each non - employee Director at Vivus elects to receive either 100% stock options or 100% restricted stock units (RSUs) o This choice does not exist at any of the
Slide 16: Board Overpays Management: Bonus for Failure
NO ACCOUNTABILITY NO ALIGNMENT WITH SHAREHOLDERS’ INTERESTS NO PAY FOR PERFORMANCE 2. The Vivus Board is Overpaid, and Overpays Management Year - Over - Year % Change 2012 Cash Bonus 2011 Cash Bonus John Slebir - VP, Business Development and General Counsel 95.4% $183,081 $93,713 Michael Miller - SV
Slide 17: Excessive Management Representation
3. Excessive Management Representation Until just recently, management controlled one - third of Vivus’ Board • With two out of six seats controlled by management they had undue influence in the boardroom and needed just one out of four “independent Directors” to deadlock the Board • Management voti
Slide 18: Board Not Aligned with Shareholders' Interests
~ $25 million $0 Value of Vivus shares SOLD by Vivus’ Board members when stock was in the $20s Value of Vivus shares PURCHASED by Vivus’ Board members when stock was in the $10s after the Qsymia launch failure IF THE BOARD BELIEVES IN VIVUS’ FUTURE, WHY AREN’T THEY BUYING STOCK? Actions speak louder
Slide 19: Mismanagement of Qsymia Launch
Qsymia has been ranked as one of the top ten blockbuster DUDS in biopharma 1 1 FierceBiotech “Analysts rank the top 10 blockbuster duds in biopharma” (April 10, 2013) 5. Mismanagement of Qsymia Launch FIRST MANHATTAN CO. 19
Slide 20: Case Study #1: Qsymia Launch Incompetence
5. Mismanagement of Qsymia Launch Case Study #1: Qsymia Launch Incompetence • Vivus was dealt a tough hand with REMS, but we believe its wounds are largely self - inflicted and result from ineffective leadership • Vivus failed to understand the market – Launch ignored the single most important deter
Slide 21: Case Study: New York Fax Prescription Failure
• NY law prohibits the faxing of prescriptions for controlled substances – Qsymia contains phentermine, a controlled substance – Vivus website did not specify that NY State physicians cannot fax Qsymia prescriptions o Management did not figure it out 10 weeks prior to launch o Management did not fig
Slide 22: Massive Spending With No Return
• Abysmal financial results in launch… • Look closely: Q4 2012 SG&A was $50 million... – Approximately $42 million of the quarterly SG&A spend is outside the sales force expense • Look closely: Q4’12A + Q1’13E, SG&A is approximately $100 million but revenues estimated at only $7 million for these si
Slide 23: Poor Steward of Capital: Headquarters Lease
Vivus Nominating and Governance Committee Charter: Nominees should possess “practical and mature business judgment, including ability to make analytical inquiries” A: In December 2012, despite the company’s alarming financial condition, the Board allowed management to enter into a new lease for the
Slide 24: Stendra is the Poster Child of Undisciplined Capital Allocation
6. The Vivus Board is a Poor Steward of Shareholder Capital Stendra is the Poster Child of Undisciplined Capital Allocation • Didn’t the Vivus Board know that the erectile dysfunction market has a high barrier to profitability? – The entrenched competition – Viagra and Cialis – have enormous marketi
Slide 25: Stendra Sale Process Has Yielded No Results
• The “sale” process for Stendra has yielded no results after 20 months – This outcome was the most likely from the beginning, and the Board should have known that • John LaMattina, former head of Pfizer global R+D, understands the ED market. In an April 2013 Forbes article, he wrote: “Stendra doesn
Slide 26: Management Willfully Obscures Critical Information From Investors
• Management blocks weekly and monthly prescription data from investors, which is highly unusual for a company of this profile • No revenue guidance – Consensus revenue estimates for FY13 have plummeted from $201 million to $57 million, and may drop further 1 • Despite 7 months of First Manhattan ur
Slide 27: Lack of Transparency (cont'd)
7. The Vivus Board and Management Lack Transparency Management Willfully Obscures Critical Information From Investors (cont’d) • No expense guidance – Management has a budget. Why do they refuse to share it with the owners? – Expenses are exploding, yet management will not provide a breakdown of how
Slide 28: Abrupt Director Resignations in April 2010
• On Friday April 30, 2010 , Vivus issued an 8 - K after the market closed announcing the resignation of the two Directors. It disclosed that: (1) On April 27, 2010 Graham Strachan, a member of the Board of Directors, notified the company that he would not be standing for re - election at the annual
Slide 29: First Manhattan Demand Under Delaware Law
First Manhattan made a demand to Vivus on April 11, 2013 under Delaware law asking for information to help answer these important questions… • Did Vivus’ exiting board members comply with all securities laws and regulations in connection with trades in Vivus stock days prior to the negative FDA AdCo
Slide 30: Vivus' Response to Demand
7. The Vivus Board and Management Lack Transparency …Vivus’ Response “FMC’s demand did not set forth a proper purpose to support FMC’s right of inspection under Delaware law.” IF VIVUS HAS NOTHING TO HIDE, WHY NOT PROVIDE THE FACTS? FIRST MANHATTAN CO. 30
Slide 31: Vivus Said vs. Reality
Vivus Said… Reality… Q: “Do you feel that where the numbers and consensus numbers have moved to that you feel confident that they better reflect the challenges to Qsymia or should we expect another round of downward revision? Leland Wilson: “I certainly don't and we're anticipating, obviously, up fr
Slide 32: Board Has Failed to Hold Management Accountable
8. The Vivus Board Has Failed In Its Responsibility To Guide Management And Hold Them Accountable When They Fail FIRST MANHATTAN CO. 32 Poor Judgment No Accountability The Qsymia launch issues with inadequate market research on price - sensitivity Qsymia launch fiasco in New York State Massi
Slide 33: Reconstitute the Vivus Board with Six Independent Nominees
First Manhattan is asking Vivus shareholders to reconstitute the Vivus Board with six highly qualified and independent Nominees. FIRST MANHATTAN CO. 33
Slide 34: A Board Overhaul is Required
A Board Overhaul is Required • Vivus’ Board and management have failed in their most basic fiduciary duty to shareholders: they did not adequately transition themselves from drug development to strong commercial leadership as Qsymia readied for launch • Without major change to the Board, we believe
Slide 35: Research Analysts Agree Change is Necessary at Vivus
A Number of Research Analysts Agree Change is Necessary at Vivus We believe many in the sell - side research community share our views on the future prospects of Vivus and its challenges*: • Cowen & Co. (4 - 26 - 13) “Our thesis on VVUS continues to be that in order for Qsymia to become a blockbuste
Slide 36: Vivus Management Will Tell You vs. The Truth Is
Vivus Management Will Tell You: But the Truth Is: • Dramatic change will be disruptive • The deteriorating status quo is exactly what needs to be disrupted • We believe our best talent will likely be poached by competitors or quit under Vivus’ failing trajectory • Conversely, we believe a winning te
Slide 37: Our Nominees: Michael Astrue
Our Nominees are Accomplished and Highly Qualified Nominee Summary of Qualifications Michael Astrue Biography Mr. Astrue most recently served as Commissioner of the Social Security Administration from 2007 to 2013, and was one of six Trustees of the Medicare & Social Security Trust Funds. He was rec
Slide 38: Our Nominees: Jon Biro
Our Nominees are Accomplished and Highly Qualified Nominee Summary of Qualifications Jon Biro Biography Mr. Biro currently serves as Executive Vice President and Chief Financial Officer at Consolidated Graphics, Inc. (NYSE: CGX), a leading commercial printing services company. Prior to Consolidated
Slide 39: Nominee: Dr. Samuel Colin
Nominee Summary of Qualifications Dr. Samuel Colin Biography Dr. Colin is a Senior Managing Director at First Manhattan Co. (FMC), an investment firm founded in 1964 with more than $14 billion in assets currently under management. Dr. Colin joined the firm in 1994, and is the founding and sole portf
Slide 40: Nominee: Dr. John Kastelein
Nominee Summary of Qualifications Dr. John Kastelein Biography Dr. Kastelein has spent his career of more than 30 years devoted to the study of medical genetics, lipidology and molecular biology. He is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center of the
Slide 41: Nominee: David Norton
Nominee Summary of Qualifications David Norton Biography Mr. Norton served in a variety of senior leadership positions during his more than 32 - year career at Johnson & Johnson (NYSE: JNJ), most recently as Company Group Chairman, Global Pharmaceuticals from 2009 until his retirement from the compa
Slide 42: Nominee: Herman Rosenman
Nominee Summary of Qualifications Herman Rosenman Biography Mr. Rosenman was most recently at Gen - Probe Inc., a medical diagnostics company, where starting in 2001 he held the role of SVP of Finance and Chief Financial Officer. At Gen - Probe, he led a company spin - off and helped lead Gen - Prob
Slide 43: Nominees Chosen for Their Skills and Experience
Our Nominees Have Been Carefully Chosen for Their Skills and Experience Nominee Successful Turnaround Experience Transaction Experience: Partnering, Co - marketing, Licensing and Company/Asset Sales New Product Launch Regulatory Financial Has Bought/Will Buy VVUS on Election Michael Astrue x x x x x
Slide 44: New Board, New Plan – Better Results For Shareholders
New Board, New Plan – Better Results For Shareholders First Manhattan Nominees have the experience, track record and necessary skills to rescue Vivus. Our independent Directors are open to all options to enhance shareholder value. The plan to rescue Vivus: 1. Day one: full strategic and operational
Slide 45: New Board, New Plan: Corporate Governance Best Practices
New Board, New Plan CREATE DURABLE VALUE FOR ALL SHAREHOLDERS Board commitment to best practices in Corporate Governance: 1. Total independence from current management 2. Only one management Director will be on the Board of Directors 3. Total alignment of the Board’s economic interests with sharehol
Slide 46: Nominees' Interests are Aligned with Vivus Shareholders
New Board, New Plan First Manhattan Nominees’ Interests are Aligned with Vivus Shareholders • FMC’s Nominees are buying stock • All six of First Manhattan’s Nominees have committed to buying additional shares in Vivus upon election – Standards for stock ownership will be adopted to further ensure Di
Slide 47: First Manhattan Interests are Fully Aligned with Vivus Shareholders
First Manhattan Interests are Fully Aligned with Vivus Shareholders Actions speak louder than words • First Manhattan is already a 9.7% shareholder – Long - term holder since 2008 – FMC has continued to buy stock after the failed Qsymia launch and has consistently purchased shares over the past five
Slide 48: The Choice is Clear for Vivus Shareholders
The Choice is Clear for Vivus Shareholders: • No accountability • Lack of transparency • Inadequate alignment with shareholder interests • A Board composed of members with strong ties to the CEO • A track record of value destruction • No credible plan for value creation • A Board that refuses to put
Slide 49: Summary
Summary • Substantial value can be unlocked at Vivus with the right strategy and leadership • The Qsymia launch is broken and we don’t believe the current team can fix it. Two or three new Directors is not enough to fix it • The current Vivus Board and management have proven that they are not equipp
Slide 50: Appendix A
_— Appendix A tencemphasis added) eeeiaene » mars eee mn Sock: fe fallow ue re: Qsyia probes Sbjct hes Totton wre: Qo prbier: ment Tn gi ene verting op siglo ne rasrbing recess. Tage selon, pelt eM Saat el el rea id ene Ge Be It ee a poy fe eect nt oe ec Sincerely, Sony ctl Wile ete roe metal Men tg